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1. Introduction 
Cytochalasin B, a metabolite from Helnzinthospori- 
urn dematioideum which is believed to block the ac- 
tivity of intracellular contractile microfilaments [ 11, 
has recently been used to investigate the mechanism 
of emiocytosis. The inhibition of non-protein bound 
iodine [2], growth hormone [3], histamine [4] and 
norepinephrine [5] release, and the potentiation of 
insulin release [6], by cytochalasin B, have both been 
used to substantiate the hypothesis that contractile 
microfilaments are involved in secretion. This inter- 
pretation depends on the assumption that cytochalasin 
B is specific in its action. However, cytochalasin B 
inhibits glucose oxidation in platelets [7], and, at 
concentrations below those used in other systems to 
inhibit secretion, it inhibits glucosamine incorpora- 
tion into mucopolysaccharides and glycoproteins [8]. 
In this report we show that the effect of cytochalasin 
B on growth hormone release depends on the exoge- 
nous substrate added; cytochalasin B inhibits prosta- 
glandin E2 induced growth hormone release in the 
presence of glucose alone, but potentiates release if 
fl-hydroxybutyrate and glutamate are also added. 
Since cytochalasin B inhibits oxidation of glucose but 
not fi-hydroxybutyrate without changing the tissue 
ATP concentration, and since glucose oxidation is 
more sensitive to cytochalasin B than is growth hor- 
mone release, it is possible that inhibition of release 
results from changes in pituitary metabolism rather 
than changes in microfilament activity. 
2. Methods 
Pituitary glands were obtained from heifers and 
incubated in Krebs-Henseleit bicarbonate buffered 
salt solution as described previously [9]. All incuba- 
tion media contained glucose (5.5 mM), and in some 
experiments sodium fi hydroxybutyrate (5.5 mM) 
and sodium glutamate (5.5 mM) were added. The 
slices were lightly blotted, weighed on a torsion 
balance, and preincubated for two successive 60 min 
periods in 1.5 ml medium to which a stock solution 
of cytochalasin B in dimethylsulphoxide (5 mg/ml) 
or an equal volume of dimethylsulphoxide had been 
added. They were then incubated for 60 min in 1 .O 
ml of the same medium with or without prostaglandin 
E, (1 PM). 
At the end of this incubation the media were re- 
moved for measurement of growth hormone concen- 
trations by radioimmunoassay [9], and the slices 
were quenched and homogenised in 0.5 ml H2SO4 
(2.5 N) at 0”. The homogenate was centrifuged 
(3000 g, 10 min, 4”), and 10 ~1 supernatant removed 
and diluted into 40 ~1 saturated Na, PO,, (approx. 
0.8 M) for measurement of ATP concentration by a 
modification of the method described by Stanley and 
Williams [lo] using a firefly lantern extract contain- 
ing luciferase (Sigma FLE-50). The remainder of the 
extract was deproteinised by addition of 0.5 ml 
barium acetate (1 M) followed by 0.8 ml saturated 
Na,PO,, and centrifuged (3OOOg, 30 min, 4”). The 
resultant supernatant was stored at - 15”) and the 
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concentration of cyclic 3’, 5’ AMP measured by the 
binding protein assay as described elsewhere [ 1 I ] but 
using 0.2 M potassium phosphate adjusted to pH 6.5 
instead of pH 5.5. 
The effects of cytochalasin B on oxidation of 
[U-14C] glucose or [3-14C] DLfl hydroxybutyrate 
were investigated in parallel experiments. The slices 
were preincubated in the presence or absence of 
cytochalasin B as described above, and then incubated 
for a further 60 min in 1 ml medium containing 
either [U-t4C] glucose (0.1 /-Xi, 5.5 mM) or [3-14C]DJ_ 
/I hydroxybutyrate (0.1 FCi, 5.5 mM), glucose (5.5 mM) 
and glutamate (5.5 mM). Oxidation was stopped by 
addition of 0.5 ml H,SO, (2 M) and J4C02 absorbed 
in hyamine (0.4 ml hyamine base) by shaking at room 
temperature for 120 min. The hyamine was diluted in 
10 ml toluene scintillator for determination of radio- 
activity in a liquid scintillation counter. 
3. Results and discussion 
In the presence of glucose alone, cytochalasin B 
(I 0 pg/ml) decreased the prostaglandin E2 induced 
rise in growth hormone release from 1.57 yg/mg/hr 
(table 1). The metabolism of [U-t4C] glucose to 
t4C02 was not altered by prostaglandin E,. Herte- 
lendy et al. [ 121 have reported that theophylline 
and dibutyryl cyclic AMP caused a 50% rise in pituit- 
ary production of 14C02 from [1-14C] glucose, but in 
these experiments this effect would be masked by the 
presence of label in other glucose carbons. Cytochala- 
sin B (lOpg/ml) caused a 90% inhibition of [U-14C]- 
glucose oxidation to t4C02 (table 1). Inhibition of 
this magnitude might be expected to lower tissue 
ATP concentrations and hence decrease growth 
hormone. release [ 13,141, but ATP concentrations 
were not changed after 3 hr incubation in cytochala- 
sin B. Cytochalasin B did not significantly alter the 
control or stimulated concentrations of cyclic AMP. 
If inhibition of glucose oxidation results in inhibi- 
tion of growth hormone release, then both parameters 
might be expected to be equally sensitive to cyto- 
chalasin B. It was found, however, that 2 pg/ml cyto- 
chalasin B caused 80% inhibition of [U-14C] glucose 
oxidation to 14C02, without changing prostaglandin 
Ez induced growth hormone release (table 2). It is 
therefore possible that cytochalasin B inhibits two 
separate processes with different affinities, although 
an alternative explanation is that normal growth 
hormone release can be maintained by glucose oxida- 
tion at not less than 20% of the normal rate. 
If cytochalasin B inhibits release by interacting 
with microfilaments at higher concentrations than 
those necessary to inhibit glucose oxidation, then it 
should also inhibit release in the presence of sub- 
strates whose oxidation it does not alter. Table 3 
shows that [3-t4C]p hydroxybutyrate oxidation to 
t4C02 is not affected by cytochalasin B. However, 
cytochalasin B potentiated the effect of prostaglandin 
E2 on growth hormone release by pituitaries incu- 
bated in fl hydroxybutyrate, glutamate and glucose. 
Williams and Wolff [2] reported that cytochalasin B 
(10 pg/ml) increased basal release of protein bound 
iodine from thyroid tissue, and suggested that this 
resulted from cell damage. Since neither the basal 
release of growth hormone nor the tissue ATP concen- 
tration was altered by cytochalasin B, potentiation of 
Table 1 
Effect of cytochalasin B (10 ,eg/ml) on pituitary slices incubated in the presence of glucose 
Incubation Rate of growth [ U-14C] glucose 
conditions hormone release metabolised to 14C02 
(pglmg wet/hr) (pmoles/g wet/hr) 
Control 0.60 * 0.05 (49) 0.81 * 0.09 (8) 
Prostaglandin Ez 2.17 + 0.23 0.76 i 0.08 
Cytochalasin B 0.54 k 0.05 0.09 i- 0.01 b 
Cytochalasin B 
+ Prostaglandin Ea 1.06 + 0.07 a 0.06 * 0.02 a 
__.~~~ .._~~ 
ATP 
concentration 
(pmoles/g wet) 
0.84 ?- 0.10 (26) 
0.82 i 0.05 
0.79 t 0.05 
0.70 ? 0.05 
Cyclic AMP 
concentration 
(nmoles/g wet) 
0.27 i 0.04 (13) 
1.15 i 0.13 
0.44 + 0.08 
0.84 i 0.10 
a: P < 0.001 versus prostaglandin Ez; b: P < 0.001 versus control. 
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Table 2 
Effect of cytochalasin B (2 bg/ml) on pituitary slices incubated in the presence of glucose. 
Incubation 
conditions 
Control 
Prostaglandin Et 
Cytochalasin B 
Cytochalasin B 
+ Prostaglandin Ea 
Rate of growth hormone 
release (Mg/mg wet/hr) 
0.28 ?r 0.04 (16) 
0.66 f 0.09 
0.31 f 0.04 
0.70 ? 0.08 
(U-14C]glucose metabolised 
to 14C02 (pmoles/g wet/hr) 
0.69 + 0.05 (16) 
0.63 +_ 0.07 
0.14 + 0.02 b 
0.14 + 0.02 a 
a: P < 0.001 versus prostaglandin E2 ; b: P < 0.001 versus control. 
Table 3 
Effect of cytochalasin B (10 fig/ml) on pituitary slices incubated in the presence of glucose, p hydroxybutryate and glutamate. 
Incubation 
conditions 
Rate of growth 
hormone release 
(pg/mg wet/hr) 
[3-‘4C]P 
hydroxybutyrate 
metabolized to r4C02 
(pmoles/g wet/hr) 
ATP 
concentration 
(pmoles/g wet) 
Cyclic AMP 
concentration 
(nmoles/g wet) 
Control 0.50 * 0.08 (24) 1.12 + 0.15 (8) 0.80 + 0.07 (20) 0.22 ? 0.04 (10) 
Prostaglandin Ea 1.18 * 0.20 1.4s ? 0.14 0.75 i 0.05 0.85 * 0.13 
Cytochalasin B 0.57 i 0.08 1.40 ? 0.24 0.81 ? 0.09 0.32 + 0.03 
Cytochalasin B 
+ Prostaglandin E2 1.82 * 0.18a 1.33 + 0.26 0.79 + 0.04 2.11 * 0.28b 
a: P ,< 0.02 versus prostaglandin E2; b: P < 0.001 versus prostaglandin E2. 
release was probably not caused by non-specific cell 
damage. It might however be related to the potentia- 
tion of the prostaglandin induced rise in tissue cyclic 
AMP concentration (table 3). 
We have previously reported [3] that in the 
presence of glucose cytochalasin B inhibited the 
effect of high K+ and prostaglandin E2, but not Ba2+. 
on growth hormone release. We report here that cyto- 
chalasin B can either inhibit or potentiate prosta- 
glandin induced growth hormone release depending 
on the substrate used, and that glucose metabolism is 
more sensitive to inhibition by cytochalasin B than is 
hormone release. It has been argued that cytochalasin 
B directly inhibits histamine release by inhibiting 
microfilament contraction (41, and that it directly 
potentiates insulin release by disrupting a microfila- 
mentous barrier to secretion [5]. Our observation that 
substrates whose oxidation is not inhibited by cyto- 
chalasin B are able to alter its effect on release from 
inhibition to potentiation suggests that the effect is 
at least in part on metabolism. It may be relevant to 
note that Hertelendy et al. [ 121 reported that 
theophylline and dibutyryl cyclic AMP increased 
oxidation of glucose in the rat pituitary by increasing 
flow through the pentose phosphate pathway; it is 
not yet known whether cytochalasin B inhibits forma- 
tion of glucose 6 phosphate in bovine anterior pituit- 
ary. 
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